Enlivex Therapeutics (NASDAQ:ENLV – Get Free Report) was upgraded by research analysts at EF Hutton Acquisition Co. I to a “strong-buy” rating in a research note issued to investors on Tuesday, Zacks.com reports.
Separately, HC Wainwright reduced their price objective on shares of Enlivex Therapeutics from $7.00 to $6.00 and set a “buy” rating for the company in a report on Tuesday, June 11th.
Check Out Our Latest Report on Enlivex Therapeutics
Enlivex Therapeutics Price Performance
Enlivex Therapeutics (NASDAQ:ENLV – Get Free Report) last released its quarterly earnings results on Friday, June 14th. The company reported ($0.22) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.25) by $0.03. Research analysts anticipate that Enlivex Therapeutics will post -0.81 EPS for the current fiscal year.
Institutional Trading of Enlivex Therapeutics
An institutional investor recently bought a new position in Enlivex Therapeutics stock. XTX Topco Ltd purchased a new position in Enlivex Therapeutics Ltd. (NASDAQ:ENLV – Free Report) during the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund purchased 24,820 shares of the company’s stock, valued at approximately $35,000. XTX Topco Ltd owned approximately 0.12% of Enlivex Therapeutics at the end of the most recent quarter. 1.02% of the stock is currently owned by institutional investors.
Enlivex Therapeutics Company Profile
Enlivex Therapeutics Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. Its product pipeline is the Allocetra, which is in phase II clinical trial for the treatment of organ dysfunction caused by sepsis. The company also develops Allocetra for the treatment of moderate knee osteoarthritis and end-stage knee osteoarthritis which is in phase I/II clinical trial.
Recommended Stories
- Five stocks we like better than Enlivex Therapeutics
- TSX Venture Exchange (Formerly Canadian Venture Exchange)
- Are Utility Stocks Running Out of Steam? What You Need to Know
- 10 Best Airline Stocks to Buy
- Snowflake’s Risk/Reward Profile Is Too Good To Miss
- How to Invest in Blue Chip Stocks
- Akamai: AI Tailwinds Drive Edge Computing and Security Growth
Receive News & Ratings for Enlivex Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enlivex Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.